The SFA Group Launches Environmental Division: SFA enviro
SFA, a World-Renowned Group, launches its Environmental Division: SFA enviro. Specialized in the design and manufacture of Wastewater Treatment Equipment since 1958, the group is mainly known for having revolutionized the sanitary equipment market.
New division, SFA enviro, the result of the SFA Group's International Growth Strategy.
With more than 1,000 employees in 27 countries worldwide, the SFA Group has a portfolio of leading brands, including Europelec and Aquaturbo. The Group’s core business is closely linked to the Treatment of Municipal and Industrial Wastewater with a DNA focused on the Design and Manufacturing of Aeration Equipment.
Thanks to 100 years of cumulative and international experience, SFA enviro supplies most of the equipment for Wastewater Treatment plants - from pre-treatment to sludge management - including process and treatment tanks and specific ancillary equipment used to settle, decant, aerate, and thicken Wastewater.
Inventiveness is a priority for the SFA Group: Since the beginning, the Group has never stopped looking to the future and adapting to the ever-changing Market Place. Innovation, R&D, respect for the environment and customer service are at the heart of the Group's Core values. The SFA Group is committed to offering high performance with quality products, manufactured in Europe and the USA.
Companies part of SFA enviro Division: Europelec (France), Aquasystems International N.V. (Belgium) and Aquaturbo Systems Inc (USA).
R&D Department works in partnership with French and other higher education and research institutions.
Much of the Equipment has been in service Worldwide for more than 30 to 35 years, with references in many Industrial Sectors such as Dairy Industry, Pulp and Paper, Mining, Food Processing, Meat Rendering, Brewery Industries, Oil and Gas, Pharmaceutical Industry, Sugar production, Livestock and Fish farming etc...
Prestigious Customers: AQUAFIN, METITO, VEOLIA, SEVERN TRENT, SAUR, WATERLEAU, SUEZ, VINCI, NIJHUIS, BENTLEY, PANTAREIN, MAREL, NESTLÉ, ASIATEX, APP SINAR MAS, TOTAL ENERGIES, LACTALIS, SACROFINA, TEREOS, GRUMA, AGROSUPER, UNITED UTILITIES, THAMES WATER SEVERN TRENT,YORKSHIRE WATER, VALERO, SMURFITT KAPPA etc...
The know-how of our skilled workers, some of whom have more than 30 years of experience, is perpetuated through recruitment programs and training of apprentices in the FABRICATION, MACHINING, WELDING, FITTING AND INSTALLLING PLUS COMMISSIONING.
Our brands: Aerospeed®, Aerostream®, Aircomb®, Aquafenr, Aquadecant®, Aquaeromix®, Aquadisc®, Aquafloat®, Aquatube®, Aquaturbo®, Euromix®, Europelec®, Noemi®, Screwpeller®, Sofie® and TLF®.
Learn more: www.sfa-enviro.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Contact: Louis-Serge Réal del Sarte, MarCom Director firstname.lastname@example.org
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release
Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit
Brigade-M3 European Acquisition Corp. 2021 Annual Report24.6.2022 16:59:00 CEST | Press release
Brigade-M3 European Acquisition Corp. (the “Company”), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, today published its annual report for the period 21 April 2021 to 31 December 2021. The full report can be downloaded from the Company’s website via the following link: https://www.brigadem3eac.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does n
PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop24.6.2022 16:41:00 CEST | Press release
PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220624005314/en/ PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. (Photo: Business Wire) News of the partnership was shared at an event hosted by 10KTF last night in New York. Their event was one of many hosted during the week of NFT.NYC, a conference attended by crypto industry professionals, traders, and other web3 enthusiasts. The official announcement confirms weeks of speculation after PUMA tw
Suzano outlines ESG milestone achievements and commitments at second annual ESG call24.6.2022 16:14:00 CEST | Press release
Suzano, the world’s largest hardwood pulp producer, today held its second annual ESG Call centered around its ambition to be a ‘regenerative company for a regenerative society’. Today’s ESG Call spotlighted measurable progress and ambitions across three core areas of action: climate change, biodiversity and social development. On Climate Change, the ACT initiative of the French Government and CDP scored Suzano ahead of its pulp and paper industry peers in virtually every metric. In 2021, Suzano brought forward its target for removing 40 million tons of carbon dioxide from the atmosphere from 2030 to 2025 which is being achieved through improvements to its industrial processes, such as systematically replacing the use of fossil fuels at its industrial plants with biomass, and through conversion of degraded land. As part of the company’s social commitments, Suzano launched a target in 2020 to lift 200,000 people out of poverty. This is more than pertinent, given that in Brazil, 10% of th
Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)24.6.2022 15:38:00 CEST | Press release
Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that CRYSVITA® (burosumab) be approved for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with less than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with p